Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 5/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147538 | 0.90 | KMT2A (0.45) | KMT2ATLR2CASP3EPHX2MDM4 | |
| SCHEMBL1276942 | 0.89 | KMT2A (0.46) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL1679779 | 0.89 | KMT2A (0.46) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL19220447 | 0.85 | KMT2A (0.48) | KMT2ATLR2CASP3EPHX2MDM4 | |
| SCHEMBL16330174 | 0.84 | KMT2A (0.50) | KMT2ATLR2CASP3EPHX2MDM4 | |
| SCHEMBL15183917 | 0.84 | KMT2A (0.49) | KMT2ATLR2CASP3EPHX2MDM4 | |
| SCHEMBL23044027 | 0.84 | KMT2A (0.46) | KMT2ATLR2CASP3EPHX2MDM4 | |
| SCHEMBL22558364 | 0.84 | KMT2A (0.46) | KMT2ATLR2CASP3EPHX2MDM4 | |
| SCHEMBL26966046 | 0.83 | KMT2A (0.48) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL27133612 | 0.83 | KMT2A (0.48) | KMT2ACASP3EPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283033-A1 | ANTIVIRAL CELL PENETRATING PEPTIDES | New York Blood Center (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090281041-A1 | ANTIVIRAL CELL-PENETRATING PEPTIDES | NEW YORK BLOOD CENTER | 2009-11-12 | — | — | US | disclosed |
| WO-2009137532-A1 | ANTIVIRAL CELL PENETRATING PEPTIDES | NEW YORK BLOOD CENTER (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281041-A1 | ANTIVIRAL CELL-PENETRATING PEPTIDES | ZC3HAV1, MAVS, HAVCR2 | KMT2A 4786/4885TLR2 3662/4885CASP3 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.